Product Information
TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB is a generic product labeled by Solco Healthcare US LLC, priced at $0.3567 per EA under NDC 43547044103. Its NADAC has been published 423 times since Aug 29, 2018.
FDA first approved this application on Nov 6, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12.5; 40 mg/1; mg/1
Manufacturer
Solco Healthcare US LLCNDC
43547044103
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; TELMISARTANApproval Type
Generic (ANDA)
FDA Application
ANDA209028FDA Approved
11/6/2017
TE Code
AB
On Market Since
2/5/2018
Pharmacological Classes
Price Statistics
The NADAC for TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB has been published 423 times since Aug 29, 2018, and over the history we have for it it has declined 79.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3567 per EA |
|---|---|
| All-time high | $2.2627 (Jul 10, 2019) |
| All-time low | $0.2777 (Nov 20, 2024) |
| 52-week high | $0.4030 |
| 52-week low | $0.3484 |
| Median price | $0.8727 |
| Average price | $1.0256 |
| Largest weekly change | +83.5% (Nov 22, 2023) |
| Weeks tracked | 423 |
| Tracking since | Aug 29, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Solco Healthcare US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
telmisartan and hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB, manufactured by Solco Healthcare US LLC, is $0.3567 per EA (NDC 43547044103), effective Sep 30, 2026.
How has the price of TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB changed over time?
Over the history we have for it, the NADAC for TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB has declined 79.9%. It has been tracked across 423 weekly CMS publications since Aug 29, 2018.
What are the highest and lowest recorded NADAC prices for TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB?
Since Aug 29, 2018, the NADAC for TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB has ranged from a low of $0.2777 (Nov 20, 2024) to a high of $2.2627 (Jul 10, 2019), with a median of $0.8727 per EA.
Are there cheaper alternatives to TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB in a comparable dosage form, but none are currently priced below it.
Who manufactures TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB?
TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB (NDC 43547044103) is labeled by Solco Healthcare US LLC, and CMS classifies it as a generic product.